Yes, open market would be the preferred option and fits NPs 'non-dilutive' statement. Any such deal could be a win-win as it show a commitment to the business relationship, and provide Samsung the ability to directly participate in any stock appreciation. Likely having inside information (such as FDA supporting documentation), this would make a statement about their belief in CYDYs success as they already have manufacturing expenses at risk.

The only downside with this option is that CYDY would not directly receive cash....but at this point, they need share price appreciation also to increase their value.

To be fair, NP stated no more private or PIPE offerings. I don't know if a business partnership direct offering at a higher price would be included in this statement or if considered acceptable from BOD perspective?....but this is the reason I mentioned the 'at a higher price'. Not because I prefer any further dilution, but if they need more cash do dilute a little more, I would hope that it is at rates twice where we currently sit.

I don't know that this direct offering will be closed or announced before the TO ends, so we have to just ride the wave until the tide turns? I truly hope it is and gets any remaining warrants off the sideline and resolves the financial concerns.